Cover Image
市場調查報告書

Circadian Technologies Limited:產品平台分析

Circadian Technologies Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253759
出版日期 內容資訊 英文 28 Pages
訂單完成後即時交付
價格
Back to Top
Circadian Technologies Limited:產品平台分析 Circadian Technologies Limited - Product Pipeline Review - 2015
出版日期: 2015年03月11日 內容資訊: 英文 28 Pages
簡介

Circadian Technologies Limited 是以血管內皮層生長因子(VEGF)為焦點進行血管新生為基礎的癌症治療方法研究開發的生物科技企業。

本報告提供Circadian Technologies Limited 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、各分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

Circadian Technologies Limited的基本資料

  • Circadian Technologies Limited概要
  • 主要資訊
  • 企業資料

Circadian Technologies Limited:R&D概要

  • 主要的治療範圍

Circadian Technologies Limited:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Circadian Technologies Limited:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Circadian Technologies Limited:藥物簡介

  • VGX-100
  • VGX-200 Series
  • VGX-300

Circadian Technologies Limited:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Circadian Technologies Limited:最近的開發平台趨勢

Circadian Technologies Limited:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06849CDB

Summary

Global Markets Direct's, 'Circadian Technologies Limited - Product Pipeline Review - 2015', provides an overview of the Circadian Technologies Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Circadian Technologies Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Circadian Technologies Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Circadian Technologies Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Circadian Technologies Limited's pipeline products

Reasons to buy

  • Evaluate Circadian Technologies Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Circadian Technologies Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Circadian Technologies Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Circadian Technologies Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Circadian Technologies Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Circadian Technologies Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Circadian Technologies Limited Snapshot
  • Circadian Technologies Limited Overview
    • Key Information
    • Key Facts
  • Circadian Technologies Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Circadian Technologies Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Circadian Technologies Limited - Pipeline Products Glance
    • Circadian Technologies Limited - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Circadian Technologies Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Circadian Technologies Limited - Drug Profiles
    • VGX-100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VGX-200 Series
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VGX-300
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Circadian Technologies Limited - Pipeline Analysis
    • Circadian Technologies Limited - Pipeline Products by Target
    • Circadian Technologies Limited - Pipeline Products by Route of Administration
    • Circadian Technologies Limited - Pipeline Products by Molecule Type
    • Circadian Technologies Limited - Pipeline Products by Mechanism of Action
  • Circadian Technologies Limited - Recent Pipeline Updates
  • Circadian Technologies Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Circadian Technologies Limited, Key Information
  • Circadian Technologies Limited, Key Facts
  • Circadian Technologies Limited - Pipeline by Indication, 2015
  • Circadian Technologies Limited - Pipeline by Stage of Development, 2015
  • Circadian Technologies Limited - Monotherapy Products in Pipeline, 2015
  • Circadian Technologies Limited - Out-Licensed Products in Pipeline, 2015
  • Circadian Technologies Limited - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Circadian Technologies Limited - Phase I, 2015
  • Circadian Technologies Limited - Preclinical, 2015
  • Circadian Technologies Limited - Discovery, 2015
  • Circadian Technologies Limited - Pipeline by Target, 2015
  • Circadian Technologies Limited - Pipeline by Route of Administration, 2015
  • Circadian Technologies Limited - Pipeline by Molecule Type, 2015
  • Circadian Technologies Limited - Pipeline Products by Mechanism of Action, 2015
  • Circadian Technologies Limited - Recent Pipeline Updates, 2015
  • Circadian Technologies Limited, Subsidiaries

List of Figures

  • Circadian Technologies Limited - Pipeline by Top 10 Indication, 2015
  • Circadian Technologies Limited - Pipeline by Stage of Development, 2015
  • Circadian Technologies Limited - Monotherapy Products in Pipeline, 2015
  • Circadian Technologies Limited - Pipeline by Top 10 Target, 2015
  • Circadian Technologies Limited - Pipeline by Top 10 Route of Administration, 2015
  • Circadian Technologies Limited - Pipeline by Top 10 Molecule Type, 2015
  • Circadian Technologies Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top